Erasca (NASDAQ:ERAS) Price Target Raised to $21.00

Erasca (NASDAQ:ERAS) had its price target upped by Morgan Stanley from $12.00 to $21.00 in a research report released on Monday, Marketbeat reports. They currently have an equal weight rating on the stock.

A number of other equities analysts have also recently issued reports on ERAS. Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a research report on Thursday, June 11th. Bank of America raised their target price on Erasca from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Tuesday, July 14th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Erasca in a research report on Tuesday, July 14th. Mizuho dropped their price target on Erasca from $28.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 12th. Finally, Stifel Nicolaus increased their price target on Erasca from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.64.

Erasca Stock Up 0.7%

Erasca stock opened at $19.51 on Monday. The company has a market capitalization of $6.07 billion, a PE ratio of -20.98 and a beta of 0.66. Erasca has a 12-month low of $1.33 and a 12-month high of $24.28. The firm’s fifty day moving average is $15.08 and its 200 day moving average is $13.77.

Erasca (NASDAQ:ERAS) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). Sell-side analysts expect that Erasca will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its stake in shares of Erasca by 58.0% in the second quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock valued at $27,000 after buying an additional 7,923 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in shares of Erasca during the second quarter worth about $29,000. Russell Investments Group Ltd. bought a new stake in shares of Erasca during the third quarter worth about $31,000. EntryPoint Capital LLC acquired a new stake in shares of Erasca in the 4th quarter worth about $38,000. Finally, Stifel Financial Corp acquired a new stake in shares of Erasca in the 4th quarter worth about $38,000. Institutional investors and hedge funds own 67.78% of the company’s stock.

Erasca News Summary

Here are the key news stories impacting Erasca this week:

• Negative Sentiment: Several firms, including Rosen Law Firm, Berger Montague, Bernstein Liebhard, and others, reiterated that a securities class action has been filed against Erasca and that investors who bought shares during the class period may seek lead-plaintiff status. ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
• Negative Sentiment: Some allegations in the litigation are particularly damaging, claiming Erasca misled investors about ERAS-0015’s competitive advantages, safety profile, and intellectual-property protection, and failed to disclose risks such as patent infringement exposure and a patient death. ERAS Deadline Alert: Levi & Korsinsky Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026
• Neutral Sentiment: One market note said Morgan Stanley sees Erasca’s stock price as having room to rise, offering a more constructive view that may help offset some of the legal overhang. Erasca (NASDAQ:ERAS) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Erasca Company Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.